OncoMatch/Clinical Trials/NCT06477549
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
Is NCT06477549 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Bendamustine Hydrochloride and Ruxolitinib for acute lymphoblastic leukemia.
Treatment: Bendamustine Hydrochloride · Ruxolitinib — Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning intensity and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure. Different technologies of with replete or depleted graft are associated with 7-20% of graft failures in different diseases. Fludarabine and busulfan conditioning is the most commonly used approach for a variety of diseases. In two previously completed trials of addition of either bendamustine and ruxolitinib to conditioning we observed low rates of primary graft failure with both approaches. The study is the direct randomized comparisons of these two approaches with the primary aim of reducing composite events of primary graft failure, relapse and non-relapse mortality. The stratas for the study are Disease Risk Index (DRI) and the age of the haploidentical donor (\<35 vs ≥35).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Lab requirements
Kidney function
creatinine ≤2 upper normal limits, creatinine clearance ≥40 mL/min
Liver function
AST or ALT ≤5 upper normal limits, bilirubin ≤1.5 upper normal limits
Cardiac function
ejection fraction ≥50%, no unstable angina, no stable angina NYHA class III or IV, no chronic heart failure NYHA class III or IV, no Lawn grade V arrhythmia, no myocardial infarction within 3 months
Moderate or severe cardiac disease: ejection fraction <50%, unstable angina, stable angina NYHA class III or IV, chronic heart failure NYHA class III or IV, Lawn grade V arrhythmia, myocardial infarction within 3 months before inclusion; Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper normal limits, creatinine >2 upper normal limits; Creatinine clearance < 40 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify